Similarly, targeting the CD36 fatty acid transporter with monoclonal antibodies has been demonstrated to effectively block fatty acid uptake and lipid metabolism in tumor-infiltrating Tregs, hindering their accumulation and function in melanoma models without causing systemic loss of Tregs[141]. This evidence concerns the gene CD36 and neoplasm.